Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis

British Journal of Pharmacology

Volumn 165, Issue 4, 2012, Pages 861-869

  Rossi, S ^a,b   Lo Giudice, T ^a,b   De Chiara, V ^a,b   Musella, A ^a,b   Studer, V ^a,b   Motta, C ^a,b   Bernardi, G ^a,b   Martino, G ^c   Furlan, R ^c   Martorana, A ^a,b   Centonze, D ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Institute of Experimental Neurology INSPE   (Italy)

Author keywords

EAE; EPSC; glutamate; multiple sclerosis; neurodegeneration; striatum

Indexed keywords

FINGOLIMOD; GLUTAMIC ACID;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENDRITE; DRUG EFFECT; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SYNAPSE; SYNAPTIC TRANSMISSION;

ANIMALS; DENDRITIC SPINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GLUTAMIC ACID; GLYCOPROTEINS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; PEPTIDE FRAGMENTS; PROPYLENE GLYCOLS; SPHINGOSINE; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84856254699     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01579.x     Document Type: Article

References (53)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Amor S, Puentes F, Baker D, van der Valk P, (2010). Inflammation in neurodegenerative diseases. Immunology 129: 154-169.
3. Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN, et al,. (2007). FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74: 307-316. (Pubitemid 47368881)
4. Bates D, (2011). Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 76: S14-S25.
5. Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T, (2003). Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278: 47408-47415. (Pubitemid 37523181)
6. Bolton C, Paul C, (1997). MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 282: 397-402. (Pubitemid 27425567)
7. Brinkmann V, (2009). FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158: 1173-1182.
8. Brinkmann V, Cyster JG, Hla T, (2004). FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4: 1019-1025. (Pubitemid 38868590)
9. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al,. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 883-897.
10. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, et al,. (2009). Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 29: 3442-3452.
11. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G, (2010). The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 17: 1083-1091.
12. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al,. (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108: 751-756.
13. Chun J, Hartung HP, (2010). Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91-101.
14. Cianfoni A, Niku S, Imbesi SG, (2007). Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28: 272-277. (Pubitemid 46281044)
15. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al,. (2010). TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
16. Compston A, Coles A, (2008). Multiple sclerosis. Lancet 372: 1502-1517.
17. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG, (2004). Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U S A 101: 8168-8173. (Pubitemid 38698072)
18. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, et al,. (2008). Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117: 77-93. (Pubitemid 350192672)
19. Dutta R, Trapp BD, (2010). Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 93: 1-12. doi:10.1016/j.pneurobio.2010.09.005.
20. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, et al,. (2007). Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469-475.
21. Geurts JJ, Wolswijk G, Bö L, van der Valk P, Polman CH, Troost D, et al,. (2003). Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 126: 1755-1766. (Pubitemid 36917335)
22. Geurts JJ, Wolswijk G, Bö L, Redeker S, Ramkema M, Troost D, et al,. (2005). Expression patterns of Group III metabotropic glutamate receptors mGluR4 and mGluR8 in multiple sclerosis lesions. J Neuroimmunol 158: 182-190. (Pubitemid 39626085)
23. Hardin-Pouzet H, Krakowski M, Bourbonnière L, Didier-Bazes M, Tran E, Owens T, (1997). Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis. Glia 20: 79-85. (Pubitemid 27207010)
24. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al,. (2010). FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401.
25. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al,. (2005). FTY720 sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2: 439-448.
26. Lee CW, Choi JW, Chun J, (2010). Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Arch Pharm Res 33: 1567-1574.
27. MacLennan AJ, Carney PR, Zhu WJ, Chaves AH, Garcia J, Grimes JR, et al,. (2001). An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosin 1-phosphate receptor in neuronal excitability. Eur J Neurosci 14: 203-209. (Pubitemid 32777628)
28. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360. (Pubitemid 38133663)
29. Matute C, Alberdi E, Domercq M, Pérez-Cerdá F, Pérez-Samartín A, Sánchez-Gõmez MV, (2001). The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 24: 224-230. (Pubitemid 32204379)
30. Miron VE, Schubart A, Antel JP, (2008). Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 274: 13-17.
31. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, et al,. (2008). Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 18: 52-61.
32. Nishimura H, Akiyama T, Irei I, Hamazaki S, Sadahira Y, (2010). Cellular localization of sphingosine-1-phosphate receptor 1 expression in the human central nervous system. J Histochem Cytochem 58: 847-856.
33. Ohgoh M, Hanada T, Smith T, Hashimoto T, Ueno M, Yamanishi Y, et al,. (2002). Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J Neuroimmunol 125: 170-178. (Pubitemid 34327467)
34. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al,. (2007). Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316: 295-298. (Pubitemid 46633109)
35. Pitt D, Werner P, Raine CS, (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67-70. (Pubitemid 30048528)
36. Plaut GS, (1987). Effectiveness of amantadine in reducing relapses in multiple sclerosis. J R Soc Med 80: 91-93. (Pubitemid 17007887)
37. Rossi S, De Chiara V, Furlan R, Musella A, Cavasinni F, Muzio L, et al,. (2010). Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 24: 1379-1385.
38. Rossi S, Muzio L, De Chiara V, Grasselli G, Musella A, Musumeci G, (2011). Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 25: 947-956.
39. Sarchielli P, Greco L, Floridi A, Floridi A, Gallai V, (2003). Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 60: 1082-1088. (Pubitemid 36975795)
40. Schubart A, Seabrook T, Rausch M, Gemayel J, Hoyer D, Dev KK, et al,. (2007). CNS mediated effects of FTY720 (fingolimod) in EAE. AAN Annual Meeting, Poster P07.101.
41. Sim-Selley LJ, Goforth PB, Mba MU, Macdonald TL, Lynch KR, Milstien S, et al,. (2009). Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS. J Neurochem 110: 1191-1202.
42. Smith T, Groom A, Zhu B, Turski L, (2000). Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6: 62-66. (Pubitemid 30048527)
43. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D, (2005). Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128: 1016-1025. (Pubitemid 40675457)
44. Stover JF, Lowitzsch K, Kempski OS, (1997). Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. Neurosci Lett 238: 25-28. (Pubitemid 28015775)
45. Tham CS, Lin FF, Rao TS, Yu N, Webb M, (2003). Microglial activation state and lysophospholipid acid receptor expression. Int J Dev Neurosci 21: 431-443. (Pubitemid 37491477)
46. Toman RE, Payne SG, Watterson KR, Maceyka M, Lee NH, Milstien S, et al,. (2004). Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 166: 381-389.
47. Trapp BD, Nave KA, (2008). Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31: 247-269.
48. Vallejo-Illarramendi A, Domercq M, Pérez-Cerdá F, Ravid R, Matute C, (2006). Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 21: 154-164. (Pubitemid 41817315)
49. Vercellino M, Merola A, Piacentino C, Votta B, Capello E, Mancardi GL, et al,. (2007). Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 66: 732-739. (Pubitemid 47344252)
50. Wallström E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T, (1996). Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 137: 89-96. (Pubitemid 26172037)
51. Zhang YH, Fehrenbacher JC, Vasko MR, Nicol GD, (2006). Sphingosine-1-phosphate via activation of a G-protein-coupled receptor(s) enhances the excitability of rat sensory neurons. J Neurophysiol 96: 1042-1052. (Pubitemid 44371500)
52. Zhu B, Luo L, Moore GR, Paty DW, Cynader MS, (2003). Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis. Am J Pathol 162: 1639-1650. (Pubitemid 36512847)
53. Ziehn MO, Avedisian AA, Tiwari-Woodruff S, Voskuhl RR, (2010). Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 90: 774-786.